The use of dapagliflozin in patients with metabolic dysfunction-associated steatohepatitis (MASH) resulted in a higher ...

Mumbai: Parexel, a clinical research organisation (CRO) providing the full range of Phase I to IV clinical development ...

Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

Althera Laboratories, a pharmaceutical company leveraging its deep expertise in cardiovascular and metabolic diseases to develop innovative treatments, today announced a significant strategic ...

New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according ...

A drug commonly used to treat type 2 diabetes may also help improve a serious liver condition, according to a new clinical ...

Around 3,000 lives could be saved and 5,500 hospital admissions prevented each year by changes to how people are treated for heart failure, according to a watchdog. New draft guidelines from the ...

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

Objective: This study aims to synthesize evidence on the cost-effectiveness of dapagliflozin for heart failure (HF) with all ejection fractions (EF), Including heart failure with reduced ejection ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

Key Takeaways A diabetes drug can help treat fatty liver diseaseDapagliflozin helped lower fat levels and prevent scarring in ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...